Short answer
Corteva (CTVA) filed its Q2 2025 10-Q quarterly report on Aug 7, 2025 for the quarter ended Jun 30, 2025. Quarterly revenue was $6.5B (up 5.6% year over year) with net income of $1.3B.
Q2 2025 key financials · XBRL
- Revenue
- $6.5B
- +5.6% YoY · +46.2% QoQ
- Net income
- $1.3B
- +24.8% YoY · +101.5% QoQ
- EPS (diluted)
- $1.92
- +28.0% YoY · +102.1% QoQ
Source: XBRL data from the Corteva (CTVA) Q2 2025 10-Q on SEC EDGAR. USD.
Corteva Q2 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk from EPA, USDA, FDA, and HHS funding and staff cuts delaying product approvals
- Most materially updated risk: regulatory delays enhanced by government agency resource constraints, impacting approval timelines
- Compliance risk: EPA registration required for pesticidal products, with stricter environmental and residue monitoring
- Operational risk near-term: delays in product approvals may disrupt product launches and market availability
- Financial risk not materially changed; no new liquidity or debt concerns disclosed in this filing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Corteva quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.